Table 2—

Baseline demographic, clinical, and satisfaction characteristics

Inhaled insulinSubcutaneous insulin
n3534
Sex (M/F)19/1618/16
Age (years)35.4 ± 9.0 (18.0–51.0)39.6 ± 8.7 (20.0–55.0)
Duration of diabetes (years)14.6 ± 9.3 (2.0–35.0)14.5 ± 9.5 (1.2–34.0)
Race/ethnic group
 White29 (83)26 (76)
 Black 1 (3)  1 (3) 
 Hispanic, other 5 (14) 7 (21)
Weight (kg)
 Men81.1 ± 11.3 (58.6–103.6)81.4 ± 10.5 (56.3–103.0)
 Women64.6 ± 7.0 (53.6–76.5)63.6 ± 8.1 (50.2–76.7)
BMI (kg/m2)
 Men25.1 ± 2.7 (21.0–31.0)25.9 ± 2.7 (22.0–31.0)
 Women24.5 ± 2.3 (20.0–28.0)24.3 ± 3.3 (19.0–31.0)
HbA1c (%)8.5 ± 1.1 (6.5–10.6)8.5 ± 1.1 (6.4–11.2)
Treatment satisfaction scores
 Global (overall)52.9 ± 12.9 (21–73)52.7 ± 11.2 (28–75)
 Convenience/ease of use35.4 ± 8.7 (15–48)35.4 ± 9.1 (17–50)
 Social comfort17.5 ± 5.5 (6–25)17.3 ± 4.9 (5–25)
  • Data are n, mean ± SD (range), or n (%). Variables are not statistically different between groups (P > 0.05)